The objective of this study is to investigate the morphogenetic role of CDX2 and other homeobox (-related) genes and intestine specific markers in the differentiation of esophagus epithelium into intestinal epithelium.
ID
Source
Brief title
Condition
- Gastrointestinal conditions NEC
Synonym
Research involving
Sponsors and support
Intervention
Outcome measures
Primary outcome
- Homeobox (-related) expression, including CDX2
- Expression of intestinal specific markers, including Muc 2, Villin
- Pathologic classification of the neo epithelium
Secondary outcome
nvt
Background summary
Barrett*s esophagus (BE) is characterized by specialized intestinal metaplasia
(SIM). With EMR a well-localized patch of epithelium is resected into the
submucosal layer. Regeneration of the mucosa starts at a fixed time point under
acid-controlled condition. These procedures are performed in patients with
neoplasia in Barrett*s esophagus, and early follow-up biopsies are generally
taken to evaluate radicality of the resection. The process and mechanism of
regeneration and differentiation is poorly understood. Biopsies from early
regenerating epithelium following ablation therapy provides a good opportunity
to study the process of intestinal differentiation of the human esophagus, and
its underlying factors in a time dependent manner.
Study objective
The objective of this study is to investigate the morphogenetic role of CDX2
and other homeobox (-related) genes and intestine specific markers in the
differentiation of esophagus epithelium into intestinal epithelium.
Study design
Biopsies will be taken at 2 weeks and 3 months after EMR to and the expression
of homeobox genes, including CDX2, intestinal differentiation markers (Villin
and MUC2), and proliferation (KI-67) by immunohistochemistry will be
determined. The presence of SIM will be determined in H&E stained sections and
confirmed by an Alcian Blue stain.
Study burden and risks
Endoscopy is considered to be a low risk intervention. Participation will take
10 minutes in total.
s-Gravendijkwal 230
3015 CE Rotterdam
Nederland
s-Gravendijkwal 230
3015 CE Rotterdam
Nederland
Listed location countries
Age
Inclusion criteria
The study will include all patients with Barrett*s esophagus who will undergo an EMR
Exclusion criteria
- < 18 years old
- Caustic lesions
- Previously treated for dysplasia
- Previously treated with radiotherapy
- Previously treated with chemotherapy
- Prior surgical treatment of the esophagus
Design
Recruitment
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
| Register | ID |
|---|---|
| CCMO | NL29683.078.09 |